Arca
Skip to content

Facioscapulohumeral muscular dystrophy

Drug research and approvals for facioscapulohumeral muscular dystrophy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 19 studies of facioscapulohumeral muscular dystrophy are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 0 approved and 9 open orphan designations naming it.

  • Recruiting worldwide: 19
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 19 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Aug 12, 2025A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of intravenous aoc 1020 for the treatment of…AOC 1020AVIDITY BIOSCIENCESOngoing
Aug 15, 2024A phase 2 open-label extension study to evaluate the long-term safety, tolerability, efficacy, and pharmacokinetics of aoc 1020 administered intravenously to…AOC 1020AVIDITY BIOSCIENCESOngoing
Apr 11, 2024A bicentric, randomized, double blind, placebo-controlled pilot study to evaluate the efficacy and safety of satralizumab in fshd1ENSPRYNGOTTAWA HOSPITAL RESEARCH INSTITUTEOngoing
Feb 6, 2024A phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of aro-dux4 in adult patients and adolescent…SRP-1001 (ARO-DUX4, ADS-010)Sarepta TherapeuticsOngoing
Mar 17, 2023A randomized, double-blind, placebo-controlled, phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory…DELPACIBART BRAXLOSIRAN (AOC 1020)AVIDITY BIOSCIENCESClosed
Feb 18, 2019An open-label extension study to evaluate the long-term effects of ace-083 in patients with fshd previously enrolled in study a083-02 and in patients with cmt…ACE-083ACCELERON PHARMA INCOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Aug 13, 2026apitegromabtreatment of facioscapulohumeral muscular dystrophyScholar Rock, Inc.Designated
Feb 2, 2026double homeobox 4 -anti-sense oligonucleotidetreatment of facioscapulohumeral muscular dystrophySolve FSHDDesignated
Nov 19, 2025small molecule inhibitor of the DUX4 transcription factortreatment of facioscapulohumeral muscular dystrophyAltay TherapeuticsDesignated
Oct 16, 2024AAV-based gene therapy expressing artificial microRNA…treatment of facioscapulohumeral muscular dystrophyArmatus BioDesignated
Nov 14, 2023Adeno-Associated Viral Vector Expressing Clustered…Treatement of facioscapulohumeral muscular dystrophyEpiCrispr Biotechnologies, Inc.Designated
Feb 13, 2023An antibody oligonucleotide conjugate, comprised of a human…Treatment of facioscapulohumeral muscular dystrophy (FSHD)Avidity Biosciences, Inc.Designated
Jan 6, 2022nandroloneTreatment of facioscapulohumeral muscular dystrophySarcomed ABDesignated
Jan 27, 2020losmapimodTreatment of Facioscapulohumeral muscular dystrophyFulcrum Therapeutics, Inc.Designated
May 23, 2018rebastinibTreatment of Facioscapulohumeral Muscular DystrophyGenea Biocells US Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.